Switzerland (CH)

Secukinumab Treatment of moderate to severe Plaque Psoriasis in the clinical Routine Care: Baseline Data from the PROSPECT Study on Psoriasis Pre-treatment (2017) Von Kiedrowski R, Korber A, Kraehn-Senftleben G, Sticherling M, Lange L, Bachhuber T, Kasparek TR, et al. Conference contribution Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis without previous Systemic Therapy for Improvement of Skin Symptoms: PASI and IGA mod. 2011-Results of the PRIME Study (2017) Reich K, Mrowietz U, Augustin M, Thaci D, Kneidl J, Hentschke C, Simang M, et al. Conference contribution Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis without prior System Therapy with respect to the Improvement of quality of life: DLQI and SF-36 Results of the PRIME Study (2017) Augustin M, Thaci D, Reich K, Mrowietz U, Kneidl J, Hentschke C, Simang M, et al. Conference contribution Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis without prior System Therapy with regard to compatibility-related Therapeutic Adherence: Safety Results of the PRIME Study (2017) Mrowietz U, Augustin M, Thaci D, Reich K, Kneidl J, Hentschke C, Simang M, et al. Conference contribution Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis with without previous Systemic Therapy for Improvement of Nail Symptoms: NAPSI Results PRIME Study (2017) Thaci D, Reich K, Mrowietz U, Augustin M, Kneidl J, Hentschke C, Simang M, et al. Conference contribution Tumor regression grading after preoperative chemoradiotherapy as prognostic factor and individual-level surrogate for disease-free survival in rectal cancer: Results of the CAO/ARO/AIO-04 multicentre, open-label, randomised, phase 3 trial (2017) Fokas E, Stroebel P, Fietkau R, Ghadimi M, Liersch T, Grabenbauer G, Hartmann A, et al. Conference contribution Quality assurance guidelines for superficial hyperthermia clinical trials: I. Clinical requirements (2017) Trefna HD, Crezee H, Schmidt M, Marder D, Lamprecht U, Ehmann M, Hartmann J, et al. Journal article PASI <= 2 corresponds to PASI 90, irrespective of baseline severity: A post-hoc analysis of the PRIME-study (2017) Reich K, Sieder C, Bachhuber T, Melzer N, Sticherling M Conference contribution Erratum to: Comparative assessment of image quality for coronary CT angiography with iobitridol and two contrast agents with higher iodine concentrations: iopromide and iomeprol. A multicentre randomized double-blind trial (2017) Achenbach S, Paul JF, Laurent F, Becker HC, Rengo M, Caudron J, Leschka S, et al. Journal article, Erratum Spatio-Temporal Analysis of Epidemic Phenomena Using the R Package surveillance (2017) Meyer S, Held L, Höhle M Journal article